Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy.

Autor: McDermott MSJ; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland., Browne BC; Cancer Research Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research Sydney, Sydney, NSW, Australia., Conlon NT; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland., O'Brien NA; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA., Slamon DJ; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA., Henry M; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland., Meleady P; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland., Clynes M; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland., Dowling P; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.; Department of Biology, National University of Ireland, Maynooth, Maynooth, Co, Kildare, Ireland., Crown J; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.; Department of Medical Oncology, St Vincent's University Hospital, Elm Park, Dublin 4, Ireland., O'Donovan N; Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland. Norma.ODonovan@dcu.ie.

Publikováno v: Molecular cancer [Mol Cancer] 2023 Oct 30; Vol. 22 (1), pp. 175. Date of Electronic Publication: 2023 Oct 30.

Alteration in Levels of Specific miRNAs and Their Potential Protein Targets between Human Pancreatic Cancer Samples, Adjacent Normal Tissue, and Xenografts Derived from These Tumors.

Autor: O'Neill F; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland., Allen-Coyle TJ; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.; SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals, V94 T9PX Limerick, Ireland., Roche S; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland., Meiller J; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland., Conlon NT; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland., Swan N; St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Straubinger RM; Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY 14214, USA., Geoghegan J; St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., Straubinger NL; Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY 14214, USA., Conlon K; St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., McDermott R; St. Vincent's University Hospital, D04 T6F4 Dublin, Ireland., O'Sullivan F; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.; SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals, V94 T9PX Limerick, Ireland., Henry M; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland., Meleady P; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.; SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals, V94 T9PX Limerick, Ireland.; School of Biotechnology, Dublin City University, D09 K2OV Dublin, Ireland., McVey G; St. Luke's Hospital, Rathgar, D06 HH36 Dublin, Ireland., O'Connor R; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland., Moriarty M; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.; St. Luke's Hospital, Rathgar, D06 HH36 Dublin, Ireland., Clynes M; National Institute for Cellular Biotechnology, Dublin City University, D09 NR58 Dublin, Ireland.; SSPC, The Science Foundation Ireland Research Centre for Pharmaceuticals, V94 T9PX Limerick, Ireland.

Publikováno v: Life (Basel, Switzerland) [Life (Basel)] 2023 Feb 22; Vol. 13 (3). Date of Electronic Publication: 2023 Feb 22.

Could MicroRNAs Be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview.

Autor: Di Fiore R; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta.; Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA., Suleiman S; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta., Pentimalli F; Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, I-80131 Napoli, Italy., O'Toole SA; Departments of Obstetrics and Gynaecology and Histopathology, Trinity St James's Cancer Institute, Trinity College Dublin, 8 Dublin, Ireland., O'Leary JJ; Department of Histopathology, Trinity St James's Cancer Institute, Trinity College Dublin, 8 Dublin, Ireland., Ward MP; Department of Histopathology, Trinity St James's Cancer Institute, Trinity College Dublin, 8 Dublin, Ireland., Conlon NT; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, 9 Dublin, Ireland., Sabol M; Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia., Ozretić P; Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia., Erson-Bensan AE; Department of Biological Sciences, Middle East Technical University, Ankara 06810, Turkey., Reed N; Beatson Oncology Centre, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G12 0YN, UK., Giordano A; Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.; Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy., Herrington CS; Cancer Research UK Edinburgh Centre, Western General Hospital, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK., Calleja-Agius J; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2021 Apr 07; Vol. 22 (8). Date of Electronic Publication: 2021 Apr 07.

GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors—Current Challenges and Future Directions

Autor: Di Fiore R; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta.; Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA., Suleiman S; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta., Ellul B; Centre for Molecular Medicine & Biobanking, University of Malta, MSD 2080 Msida, Malta., O'Toole SA; Departments of Obstetrics and Gynaecology and Histopathology, Trinity St James's Cancer Institute, Trinity College Dublin, 8 Dublin, Ireland., Savona-Ventura C; Department of Obstetrics and Gynaecology, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta., Felix A; Department of Pathology, Campo dos Mártires da Pátria, Instituto Portugues de Oncologia de Lisboa, NOVA Medical School, UNL, 130, 1169-056 Lisboa, Portugal., Napolioni V; Genomic And Molecular Epidemiology (GAME) Lab., School of Biosciences and Veterinary Medicine, University of Camerino, 62032 Camerino, Italy., Conlon NT; National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, 9 Dublin, Ireland., Kahramanoglu I; Department of Gynecologic Oncology, Emsey Hospital, 3400 Istanbul, Turkey., Azzopardi MJ; Directorate for Health Information and Research, 95, PTA1313 G'Mangia, Malta., Dalmas M; Office of the Chief Medical Officer, Department of Policy in Health, Ministry for Health, 15, Merchants Street, VLT1171 Valletta, Malta., Calleja N; Directorate for Health Information and Research, 95, PTA1313 G'Mangia, Malta., Brincat MR; Department of Obstetrics and Gynaecology, Mater Dei Hospital, Triq Dun Karm, MSD 2090 Msida, Malta., Muscat-Baron Y; Department of Obstetrics and Gynaecology, Mater Dei Hospital, Triq Dun Karm, MSD 2090 Msida, Malta., Sabol M; Laboratory for Hereditary Cancer, Division of Molecular Medicine, Ruđer Bošković Institute, 10000 Zagreb, Croatia., Dimitrievska V; University of American College, 1000 Skopje, North Macedonia., Yordanov A; Department of Gynecologic Oncology, Medical University Pleven, 5800 Pleven, Bulgaria., Vasileva-Slaveva M; Department of Surgery, Alexandrovska University Hospital, 1431 Sofia, Bulgaria., von Brockdorff K; Sir Anthony Mamo Oncology Centre, Department of Oncology and Radiotherapy, Mater Dei Hospital, MSD2090 Msida, Malta., Micallef RA; Sir Anthony Mamo Oncology Centre, Department of Oncology and Radiotherapy, Mater Dei Hospital, MSD2090 Msida, Malta., Kubelac P; Department of Medical Oncology, The Oncology Institute 'Prof. Dr. Ion Chiricuţă', 34-36 Republicii Street, 400015 Cluj-Napoca, Romania.; Department of Oncology, 'Iuliu Hatieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania., Achimaș-Cadariu P; Department of Oncology, 'Iuliu Hatieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.; Department of Surgical Oncology, The Oncology Institute 'Prof. Dr. Ion Chiricuta', 400015 Cluj-Napoca, Romania., Vlad C; Department of Oncology, 'Iuliu Hatieganu' University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.; Department of Surgery, The Oncology Institute 'Prof. Dr. Ion Chiricuta', 400015 Cluj Napoca, Romania., Tzortzatou O; Biomedical Research Foundation of the Academy of Athens, Soranou Efesiou 4 str., 11527 Athens, Greece., Poka R; Institute of Obstetrics and Gynaecology, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary., Giordano A; Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.; Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy., Felice A; Centre of Molecular Medicine and BioBanking, Department of Physiology & Biochemistry, Faculty of Medicine & Surgery, University of Malta, MSD 2080 Msida, Malta., Reed N; Beatson Oncology Centre, Gartnavel General Hospital, 1053 Great Western Road, Glasgow G120YN, UK., Herrington CS; Cancer Research UK Edinburgh Centre, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK., Faraggi D; Department of Statistics, University of Haifa, Haifa 31905, Israel., Calleja-Agius J; Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, MSD 2080 Msida, Malta.

Publikováno v: Cancers [Cancers (Basel)] 2021 Jan 27; Vol. 13 (3). Date of Electronic Publication: 2021 Jan 27.

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.

Autor: Canonici A; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Browne AL; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Ibrahim MFK; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Fanning KP; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Roche S; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Conlon NT; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., O'Neill F; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Meiller J; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Cremona M; Medical Oncology Group, Department of Molecular Medicine, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland., Morgan C; Medical Oncology Group, Department of Molecular Medicine, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland., Hennessy BT; Medical Oncology Group, Department of Molecular Medicine, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland., Eustace AJ; National Institute for Cellular Biotechnology, Dublin City University, Whitehall, Glasnevin, Dublin 9, Ireland., Solca F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., O'Donovan N; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland., Crown J; National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2020 Jan 28; Vol. 12, pp. 1758835919897546. Date of Electronic Publication: 2020 Jan 28 (Print Publication: 2020).